Priority review and Project Orbis evaluation advance potential post-neoadjuvant use of trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease after neoadjuvant ...
Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.
Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results